State-of-the-art equipment

We support The Royal Marsden by investing in state-of-the-art equipment to provide patients with more treatment options.

Patient being treated by CyberKnife
In 2023/24 we supported The Royal Marsden with a
£5.1 million equipment grant
as well as a £1.39 million grant to support the digitisation of the hospital’s histopathology service.
A Biomedical Scientist in a white lab coat smiling and standing with stainers and a piece of white equipment in a hospital medical room
Aanzi Albert, Biomedical Scientist

Providing the latest equipment for more effective treatment

We fund state-of-the-art equipment that provides faster diagnosis, more effective and less invasive treatments, and quicker recovery times. It’s essential that clinicians, scientists and researchers have access to the latest equipment as this is also key to achieving major breakthroughs in cancer research.

The equipment grant has funded a new linear accelerator to introduce the most recent advancement in radiotherapy technology, known as online Adaptive Radiotherapy (oART). This technology enables treatment to be adapted daily in real time for each patient, depending on the position of the tumour and anatomy. Targeting the tumour more precisely minimises damage to healthy tissue and helps to reduce side effects for patients.

The £1.39 million Digital Histopathology grant, awarded in 2023/24, together with previous funding awarded in 2021/22, has supported the digitisation of the histopathology department, where patients’ tissue samples are processed and examined, enabling an accurate diagnosis to be made. With our funding, the hospital has purchased and installed state-of-the-art scanners and slide printers, integral to the transformation of this service.

"A strong digital pathology diagnostic service with a comprehensive digital database is a foundation stone to opening up many more avenues for our research, so we can enable patients to live longer and better lives."

Prof Manuel Salto-Tellez, Clinical Consultant at The Royal Marsden and Professor of Integrated Pathology at The Institute of Cancer Research, London.